Sion, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer. 2011;128:1269?9. 25. Shen H, Wang L, Ge X, Jiang CF, Shi ZM, Li DM, et al. MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer. Oncotarget. 2016;7:20728?2. 26. Dong S, Jin M, Li Y, Ren P, Liu J. miR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12. Oncol Rep. 2016;35:2151?. 27. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194. 28. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44?3. 29. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816. 30. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69:7569?6. 31. Gallardo E, Navarro A, Vi las N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903?. 32. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007;104: 15472?. 33. Ma Y, Qin H, Cui Y. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem Biophys Res Commun. 2013;441:958?3. 34. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70:7027?0.Submit your next manuscript to BioMed Central and we will help you at every step:?We accept pre-submission inquiries ?Our selector tool helps you to find the most relevant BFA site journal ?We provide round the clock customer support ?Convenient online submission ?Thorough peer review ?Inclusion in PubMed and all major indexing PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25768400 services ?Maximum visibility for your research Submit your manuscript at www.biomedcentral.com/submit
Liu et al. Journal of Experimental Clinical Cancer Research (2016) 35:170 DOI 10.1186/s13046-016-0445-RESEARCHOpen AccessTripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signalingmediated epithelial-mesenchymal transition in cervical cancerTian-Yu Liu1, Jian Chen2, Chun-Liang Shang1, Hong-Wei Shen1, Jia-Ming Huang1, Yan-Chun Liang1, Wei Wang1, Yun-He Zhao1, Duo Liu1, Man Shu3, Lu-Yan Guo1, Zheng Hu1* and Shu-Zhong Yao1*AbstractBackground: TRIM62 (tripartite motif containing 62) has been found to act as a tumor suppressor of several cancers. However, its precise biological role and related mechanism remain unknown in cervical cancer (CC). Methods: Quantitative Real-time PCR and western blot were adopted to detect the mRNA and protein expression level of TRIM62 in both human CC cell lines and tissues. Immunohistochemistry was used to measure the TRIM62 expression in 30 normal cervical and 189 CC tissues. Univariate and multivariate Cox regression analyses and Kaplan eier survival analyses performed to investigate the association between TRIM62 expression and CC patients’ prognosis. The effect of TRIM62 on CC growth and metastasis was st.
